402 related articles for article (PubMed ID: 27974048)
1. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
[TBL] [Abstract][Full Text] [Related]
2. Regulation of tau pathology by the microglial fractalkine receptor.
Bhaskar K; Konerth M; Kokiko-Cochran ON; Cardona A; Ransohoff RM; Lamb BT
Neuron; 2010 Oct; 68(1):19-31. PubMed ID: 20920788
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.
Li Y; Liu L; Barger SW; Griffin WS
J Neurosci; 2003 Mar; 23(5):1605-11. PubMed ID: 12629164
[TBL] [Abstract][Full Text] [Related]
4. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.
Maphis N; Xu G; Kokiko-Cochran ON; Jiang S; Cardona A; Ransohoff RM; Lamb BT; Bhaskar K
Brain; 2015 Jun; 138(Pt 6):1738-55. PubMed ID: 25833819
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
6. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease.
Culbert AA; Skaper SD; Howlett DR; Evans NA; Facci L; Soden PE; Seymour ZM; Guillot F; Gaestel M; Richardson JC
J Biol Chem; 2006 Aug; 281(33):23658-67. PubMed ID: 16774924
[TBL] [Abstract][Full Text] [Related]
7. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
[TBL] [Abstract][Full Text] [Related]
8. Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.
Barron MR; Gartlon J; Dawson LA; Atkinson PJ; Pardon MC
Front Immunol; 2020; 11():293. PubMed ID: 32194553
[TBL] [Abstract][Full Text] [Related]
9. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation.
Sheng JG; Jones RA; Zhou XQ; McGinness JM; Van Eldik LJ; Mrak RE; Griffin WS
Neurochem Int; 2001; 39(5-6):341-8. PubMed ID: 11578769
[TBL] [Abstract][Full Text] [Related]
11. Effect of c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation.
Cao M; Liu F; Ji F; Liang J; Liu L; Wu Q; Wang T
Behav Brain Res; 2013 Jan; 237():249-55. PubMed ID: 23026374
[TBL] [Abstract][Full Text] [Related]
12. IL-1β-induced and p38
Kulawik A; Engesser R; Ehlting C; Raue A; Albrecht U; Hahn B; Lehmann WD; Gaestel M; Klingmüller U; Häussinger D; Timmer J; Bode JG
J Biol Chem; 2017 Apr; 292(15):6291-6302. PubMed ID: 28223354
[TBL] [Abstract][Full Text] [Related]
13. Dephosphorylated rather than hyperphosphorylated Tau triggers a pro-inflammatory profile in microglia through the p38 MAPK pathway.
Perea JR; Ávila J; Bolós M
Exp Neurol; 2018 Dec; 310():14-21. PubMed ID: 30138606
[TBL] [Abstract][Full Text] [Related]
14. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
15. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
16. Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice.
Funding AT; Johansen C; Gaestel M; Bibby BM; Lilleholt LL; Kragballe K; Iversen L
J Invest Dermatol; 2009 Apr; 129(4):891-8. PubMed ID: 18987672
[TBL] [Abstract][Full Text] [Related]
17. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia.
Tanno M; Bassi R; Gorog DA; Saurin AT; Jiang J; Heads RJ; Martin JL; Davis RJ; Flavell RA; Marber MS
Circ Res; 2003 Aug; 93(3):254-61. PubMed ID: 12829618
[TBL] [Abstract][Full Text] [Related]
18. Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer's mouse models.
Schnöder L; Gasparoni G; Nordström K; Schottek A; Tomic I; Christmann A; Schäfer KH; Menger MD; Walter J; Fassbender K; Liu Y
FASEB J; 2020 Jul; 34(7):9628-9649. PubMed ID: 32475008
[TBL] [Abstract][Full Text] [Related]
19. Kinase activities increase during the development of tauopathy in htau mice.
Kelleher I; Garwood C; Hanger DP; Anderton BH; Noble W
J Neurochem; 2007 Dec; 103(6):2256-67. PubMed ID: 17908241
[TBL] [Abstract][Full Text] [Related]
20. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
